Cargando…

Beta-D-Glucan in Patients with Haematological Malignancies

(1-3)-beta-D-glucan (BDG) is an almost panfungal marker (absent in zygomycetes and most cryptococci), which can be successfully used in screening and diagnostic testing in patients with haematological malignancies if its advantages and limitations are known. The aim of this review is to report the d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mikulska, Malgorzata, Balletto, Elisa, Castagnola, Elio, Mularoni, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706797/ https://www.ncbi.nlm.nih.gov/pubmed/34947028 http://dx.doi.org/10.3390/jof7121046

Ejemplares similares

Bacterial Infections in Hematopoietic Stem Cell Transplant Recipients
por: Balletto, Elisa, et al.
Publicado: (2015)

Prophylaxis and Empirical Therapy of Infection in Cancer Patients
por: Castagnola, Elio, et al.
Publicado: (2015)

Beta-Glucans of Cereals: Functional and Technological Properties
por: Lante, Anna, et al.
Publicado: (2023)

Tuberculosis in Patients with Haematological Malignancies
por: Anibarro, Luis, et al.
Publicado: (2014)

Sensitivity of Serum Beta-D-Glucan in Candidemia According to Candida Species Epidemiology in Critically Ill Patients Admitted to the Intensive Care Unit
por: Mikulska, Malgorzata, et al.
Publicado: (2022)

Survival of critically ill patients with haematological malignancies compared with patients without haematological malignancy
por: Pugh, R, et al.
Publicado: (2013)

Clinical Proteomics of Biofluids in Haematological Malignancies
por: Dunphy, Katie, et al.
Publicado: (2021)

Cancer stem cells in haematological malignancies
por: Zagozdzon, Radoslaw, et al.
Publicado: (2015)

The hypoxia signalling pathway in haematological malignancies
por: Irigoyen, Marta, et al.
Publicado: (2017)

The Application of CAR-T Cells in Haematological Malignancies
por: Skorka, Katarzyna, et al.
Publicado: (2020)

Targeting hypoxia in solid and haematological malignancies
por: Harris, Bill, et al.
Publicado: (2022)

Early integration of palliative care for patients with haematological malignancies
por: Shaulov, Adir, et al.
Publicado: (2022)

Edible Mushrooms and Beta-Glucans: Impact on Human Health
por: Cerletti, Chiara, et al.
Publicado: (2021)

Beta-glucans in the treatment of diabetes and associated cardiovascular risks
por: Chen, Jiezhong, et al.
Publicado: (2008)

Detection of Beta-Glucan Contamination in Nanotechnology-Based Formulations
por: Neun, Barry W., et al.
Publicado: (2020)

The Role of miRNA in Haematological Malignancy
por: Gounaris-Shannon, Stephanie, et al.
Publicado: (2013)

Breast imaging findings in haematological malignancies
por: Glazebrook, K. N., et al.
Publicado: (2014)

PARP Inhibitors and Haematological Malignancies—Friend or Foe?
por: Skelding, Kathryn A., et al.
Publicado: (2021)

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
por: Bishton, Mark J., et al.
Publicado: (2010)

Long Non-Coding RNAs in Haematological Malignancies
por: Garitano-Trojaola, Andoni, et al.
Publicado: (2013)

Components of the Lectin Pathway of Complement in Haematologic Malignancies
por: Cedzyński, Maciej, et al.
Publicado: (2020)

Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies
por: Mynott, Rachel L., et al.
Publicado: (2023)

Immune-modulatory effects of dietary Yeast Beta-1,3/1,6-D-glucan
por: Stier, Heike, et al.
Publicado: (2014)

Clinical Outcomes after Oat Beta-Glucans Dietary Treatment in Gastritis Patients
por: Gudej, Sylwia, et al.
Publicado: (2021)

Beta Glucan: Health Benefits in Obesity and Metabolic Syndrome
por: El Khoury, D., et al.
Publicado: (2012)

Beta Glucan: Supplement or Drug? From Laboratory to Clinical Trials
por: Vetvicka, Vaclav, et al.
Publicado: (2019)

Functional activities of beta-glucans in the prevention or treatment of cervical cancer
por: Chaichian, Shahla, et al.
Publicado: (2020)

Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
por: Cesaro, Simone, et al.
Publicado: (2022)

Beta-Glucan as Wall Material in Encapsulation of Elderberry (Sambucus nigra) Extract
por: Sobieralska, Małgorzata, et al.
Publicado: (2019)

Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms
por: Vanni, Daniele, et al.
Publicado: (2022)

Targeting Metabolism and Autophagy in the Context of Haematologic Malignancies
por: Banerji, Versha, et al.
Publicado: (2012)

CAR T Cell Immunotherapy Beyond Haematological Malignancy
por: Hupperetz, Cedric, et al.
Publicado: (2022)

Beta-Glucan in Foods and Health Benefits
por: Aoe, Seiichiro
Publicado: (2021)

Nocardiosis and elevated beta-d-glucan in solid organ transplant recipients
por: Ringer, Matthew, et al.
Publicado: (2021)

Vitamin D and Beta-Glucans Synergically Stimulate Human Macrophage Activity
por: Bergandi, Loredana, et al.
Publicado: (2021)

Inhalation of (1-->3)-beta-D-glucan causes airway eosinophilia.
por: Fogelmark, B, et al.
Publicado: (2001)

Experience of using beta-D-glucan assays in the intensive care unit
por: Dagens, A., et al.
Publicado: (2018)

PSYCHOLOGICAL ASPECTS OF HAEMATOLOGICAL MALIGNANCIES
por: Kulhara, P., et al.
Publicado: (1990)

360. The diagnostic sensitivity of beta-D-glucan assay in patients with chronic disseminated candidiasis
por: Son, Hyo-Ju
Publicado: (2022)

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
por: Smith, A, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_54l89du441rup2i9pkfh10iaq5